Slide 1: CARPO Trial Topline Results
Exhibit 99.2 Developing Novel Therapies for Acute Inflammatory and Immunologic Diseases CARPO Trial Topline Results June 27, 2024 1 Confidential
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica’s business strategy and clinical development plans; the design and potential benefits of CalciMedica’s product candidates; CalciMedica’s ongoing an
Slide 3: CARPO Topline Takeaways
CARPO Topline Takeaways • Primary objective was met with a dose response for multiple endpoints • Statistically significant for time to solid food tolerance in high hematocrit patients • Statistically significant for severe organ failure in the entire population • Auxora was well-tolerated • Auxora
Slide 4: Auxora Clinically Active and Well-Tolerated in Multiple Phase 2 Trials
Auxora Clinically Active and Well-Tolerated in Multiple Phase 2 Trials Population Trial Size Results Pancreas • Topline results show: Ø Improvement in clinically significant endpoints Acute Pancreatitis Ø Statistically significant dose response for time to solid food tolerance in patients with hyper
Slide 5: Differentiated Pipeline in Acute and Chronic Inflammatory and Immunologic Diseases
Differentiated Pipeline in Acute and Chronic Inflammatory and Immunologic Diseases Phase of Development 1 Indication Anticipated Milestones Program Preclinical Phase 1 Phase 2 Phase 3 Acute Disease (IV) CARPO Phase 2b trial topline data released; Auxora Acute Pancreatitis Final data expected in 2H20
Slide 6: CARPO Phase 2b Clinical Trial in AP
CARPO Phase 2b Clinical Trial in AP Primary End Point Secondary Endpoints • Length of hospital stay • Time to solid food tolerance • Time to medically indicated discharged • Severe organ failure • Re-hospitalizations • Necrosis as determined by CT MEDIUM DOSE (n=54) Primary Objective: Dose Response
Slide 7: Defining Who to Treat: Patients with Acute Critical Illnesses
Defining Who to Treat: Patients with Acute Critical Illnesses Vincent, J. L., Opal, S. M., & Marshall, J. C. (2010). Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment 7 decisions. Critical care medicine, 38(1), 283-287.
Slide 8: Enrich CARPO for Patients with Hyperinflammatory Acute Pancreatitis
Enrich CARPO for Patients with Hyperinflammatory Acute Pancreatitis • CARPO added inclusion criteria to enroll pre-specified subgroup of patients with an elevated hematocrit • Inclusion criteria in addition to SIRS – Hematocrit ≥44% for men or ≥40% for women, established biomarker for inflammation –
Slide 9: CARPO Baseline Characteristics
CARPO Baseline Characteristics Note: mITT was 214 patients as 2 enrolled patients did not receive study drug 9
Slide 10: Time to Solid Food Tolerance
Time to Solid Food Tolerance Statistical significance achieved on dose response in patients with hyperinflammatory AP *One hematocrit missing at baseline Determination of solid food tolerance • Patient offered a low fat, ≥500-calorie solid meal • Patient consumes ≥50% of the meal without vomiting or
Slide 11: Length of Hospital Stay
Length of Hospital Stay Placebo 2.0 mg/kg 1.0 mg/kg 0.5 mg/kg N=53 N=53 N=56 N=52 LOS mITT Median days 5.0 4.0 5.0 5.5 LOS mITT Mean days 7.1 5.9 5.9 7.6 LOS High Mean days 7.8 6.3 5.7 7.9 Hematocrit 22-30 days n subjects (%) 3 (5.7) 0 (0.0) 1 (1.8) 3 (5.8) 11
Slide 12: Severe Organ Failure
Severe Organ Failure Statistical significance achieved on dose response Placebo 2.0 mg/kg 1.0 mg/kg 0.5 mg/kg N=53 N=53 N=56 N=52 Severe Respiratory (%) 4/53 (7.5) 2/53 (3.8) 2/56 (3.6) 5/52 (9.6) Severe Renal (%) 1/53 (1.9) 0/53 (0.0) 1/56 (1.8) 2/52 (3.8) Severe Cardiovascular (%) 1/53 (1.9) 1/53
Slide 13: Serious Adverse Event Summary
Serious Adverse Event Summary Placebo 2.0 mg/kg 1.0 mg/kg 0.5 mg/kg Total Auxora N=53 N=53 N=56 N=52 N=161 Number of TESAEs 20 14 21 23 58 Patients discontinuing study 3 2 2 2 6 drug due to TESAEs Patients with TEAEs leading 1 0 1 0 1 to death TESAE=treatment emergent serious adverse event TEAE=trea
Slide 14: Conclusions and Next Steps
Conclusions and Next Steps • Auxora is ready for Phase 3 clinical development pending FDA discussion • Primary objective met with a dose response for multiple endpoints • Auxora well-tolerated • Reduction in severe organ failure increases confidence in KOURAGE AKI trial • Next steps: further analysi